Abstract
Abstract
Enterocutaneous fistulas (ECFs) represent abnormal communications between the gastrointestinal tract and the skin. Nowadays, the majority (~80%) of ECFs develops secondary to abdominal surgeries; alternative, less common causes include chronic inflammatory bowel diseases (IBD) such as Crohn’s disease, tumours, and radiation enteritis in descending order of frequency. These rare disorders require thorough patient assessment and multidisciplinary management to limit the associated morbidity and mortality. This pictorial review includes an overview of causes, clinical manifestations, complications and management of ECFs. Afterwards, the imaging appearances, differential diagnoses, and therapeutic options of post-surgical, IBD-related, and malignant ECFs are presented with case examples. Most of the emphasis is placed on the current pivotal role of CT and MRI, which comprehensively depict ECFs providing cross-sectional information on the underlying postsurgical, neoplastic, infectious, or inflammatory conditions. Radiographic fistulography remains a valid technique, which rapidly depicts the ECF anatomy and confirms communication with the bowel. The aim of this paper is to increase radiologists’ familiarity with ECF imaging, thus allowing an appropriate choice between medical, interventional, or surgical treatment, ultimately resulting in higher likelihood of therapeutic success.
Teaching Points
• Enterocutaneous fistulas may complicate abdominal surgery, sometimes Crohn’s disease and tumours.
• The high associated morbidity and mortality result from sepsis, malnutrition and metabolic imbalance.
• The multidisciplinary management of ECFs requires thorough imaging for correct therapeutic choice.
• Radiographic fistulography rapidly depicts fistulas and communicating bowel loops in real-time.
• Multidetector CT and MRI provide cross-sectional information on fistulas and underlying diseases.
Keywords: Enterocutaneous fistula, Malignant fistula, Crohn’s disease, Computed tomography (CT), Magnetic resonance imaging (MRI)
Introduction
Enterocutaneous fistulas (ECFs) are defined as abnormal communications between the gastrointestinal (GI) tract and the skin. Albeit relatively rare compared to past decades, ECFs still represent one of the most challenging conditions encountered in surgical practice, burdened with severe morbidity, impaired quality of life, and substantial mortality [1–3].
In recent years, specialised centres developed a robust management approach, which combines experience from surgeons, interventional radiologists, intensive care physicians, nutritionists, wound care specialists and nurses. Summarised in Table 1, this multidisciplinary treatment relies on thorough diagnostic imaging for correct patient selection and therapeutic choice: unfortunately, very limited literature exists on cross-sectional imaging of ECFs [4, 5].
Table 1.
Step no. | Treatment basics | Comments |
---|---|---|
1 | Control of sepsis | Often requiring intensive care support Imaging-guided drainage of abscess collections |
2 | Limiting output volume | Octreotide administration Bowel rest, enteral, or parenteral nutrition |
3 | Wound or skin care | Use of dressings or bags depending on output Suction or Vacuum-Assisted Closure (VAC) devices if available |
4 | Metabolic and nutritional optimisation | Adequate hydration, electrolytes balance, nutritional status Proximal versus location in the bowel influences nutritional and fluid requirements |
5 | Assessing likelihood of spontaneous closure | Versus percutaneous treatment or elective surgical repair Factors associated with favourable healing: - narrow-calibre and/or relatively long (>2 cm) ECFs, - small enteric defect or anastomotic dehiscence (<1 cm) Factors associated with probable non-healing: - presence of foreign bodies, - history of irradiation, - active infection, - untreated chronic inflammatory bowel disease, - untreated tumours, - distal obstruction |
This pictorial review relies upon experience at a tertiary referral hospital where oncologic and chronic inflammatory bowel disease (IBD) surgeries are performed. It includes an overview of causes, clinical manifestations, complications, and management of ECFs. Afterwards, the imaging appearances, differential diagnoses and therapeutic options of post-surgical, chronic inflammatory bowel diseases (IBD)-related and malignant ECFs are presented with examples. Most of the emphasis is placed on the current pivotal role of CT and MRI, which comprehensively depict ECFs providing cross-sectional information on the underlying postsurgical, neoplastic, infectious, or inflammatory disorders.
Our aim is to increase radiologists’ familiarity with ECF imaging, thus allowing an appropriate choice between medical, interventional, or surgical treatment, ultimately resulting in higher likelihood of therapeutic success.
Clinical overview of enterocutaneous fistulas
The origin of an ECF may lie anywhere along the GI tract, and is found in the small bowel, colon, stomach, and duodenum in descending order of frequency. Nowadays, the majority (75–85%) of ECFs develop postoperatively following oncologic abdominal surgery, bowel resections for Crohn’s disease (CD), ventral hernioplasty, and repeated laparotomies. The remaining, spontaneous ECFs occur secondary to IBD (mostly CD rather than indeterminate and ulcerative colitis), fistulising tumours, radiation enteritis, colonic diverticulitis, intra-abdominal sepsis, and trauma, in descending order of frequency [1–3, 6].
The hallmark clinical finding is the external fistulous opening (EFO) at the anterior or lateral abdominal wall, which is often surrounded by an inflamed, tender cutaneous region, and may sometimes be hidden beneath a skin fold, or lie in the site of a recent or still patent surgical incision. Discharge may be either intermittent or continuous, sometimes purulent or faecal. The ECF output may be quantified and categorised as low (below 200 mL/day), moderate or high (over 500 mL/day). The macroscopic and biochemical features of the effluent provide useful clues to the ECF origin [1–3, 6].
Historically, the ECF-related mortality was in excess of 50%, particularly in those patients with high-output fistulas, tumours and sepsis. During the last 15 years, the improvements in surgery, wound care, nutritional and metabolic support resulted in decreased fatality rates (8–13%) and ultimate therapeutic success after a median 6 weeks in 75–91% of patients [1–3, 6].
However, rates of nonoperative healing remain low (~20–27% of cases overall) and ECFs still represent chronic, debilitating conditions associated with prolonged intensive care unit and hospital stays. The ECF-associated morbidity arises from sepsis, malnutrition, and metabolic imbalance. The invariable fluid and electrolyte abnormalities result from the combined effect of protracted catabolic febrile state, ileus or obstruction, loss of bowel integrity, and absorption. Further complications include generalised peritonitis, abdominal wall abscesses, and necrotising fasciitis secondary to soft tissue damage by bacteria and digestive juices [7, 8].
The ECF aetiology is the single best prognostic factor and predictor of therapeutic success [9]. In fact, the cause and underlying abnormalities strongly influence the likelihood of spontaneous closure and dictate the need for additional medical, surgical, or interventional treatment; therefore, the following sections will present the postoperative, CD-related and malignant ECFs separately with their specific imaging features and therapeutic approaches [1–3, 6].
Post-surgical enterocutaneous fistulas
Clinical features
Despite improved techniques, most ECFs currently develop after surgical procedures, secondary to anastomotic leakage, disruption of repaired enterotomy, or inadvertent intraoperative bowel injury. Some series reported an alarming incidence (0.8–2%) of postsurgical ECFs, probably resulting from the increasing complexity of procedures such as cytoreductive surgery with peritonectomy. Currently, the majority of ECFs are encountered in patients operated for colorectal and ovarian cancers. Alternatively, ECFs may develop following non-oncologic surgery such as ventral hernioplasty using prosthetic mesh, or repeated laparotomies such as for adhesiolysis and recurrent bowel obstruction. In our experience, the majority of patients had complex histories including multiple surgical interventions [4, 10–12].
Post-surgical ECFs may manifest early (within the first postoperative week) with a combination of septic fever, tachycardia, and hypotension, respiratory distress, progressively distended bowel, localised or diffuse abdominal tenderness, acidosis, leukocytosis, and elevated C-reactive protein. Alternatively, ECFs may present late during prolonged postoperative hospitalisation or after discharge as a tender, erythematous, fluctuant area at the surgical incision, or laparoscopic port site; in such cases nurses often notice medication gauzes becoming wet with either bile, enteric material, or stool [2].
Radiographic fistulography: technique and appearances
Fistulography (sinography) traditionally represented the mainstay technique to investigate ECFs and currently remains useful as a complementary technique to confirm communication between the EFO and a segment of the gastrointestinal tract. In our experience, this technique is best performed with help from the referring surgeon, who probes the EFO and enters the ECF. Depending on its calibre, a venous cannula or angiographic needle, a standard syringe, a Foley-type catheter, a paediatric or nasogastric feeding tube may be used. Then, non-forceful manual injection of low-osmolar water-soluble iodinated contrast medium (CM) is performed under fluoroscopic observation. Inexpensive, rapid, and easy to perform, fistulography directly visualises the communicating small bowel (Fig. 1A, B) or colonic segment (Fig. 1C) and provides information on ECF anatomy such as calibre, length, course, and ramifications. False negative studies may result from oedema, debris, or compression by abscess or mass impeding CM flow into the intestinal lumen. However, fistulography lacks cross-sectional visualisation of mural and extraluminal pathology upstream, downstream, and at site of the ECF [4, 5].
CT techniques, appearances, and differential diagnoses
Nowadays the vast majority of patients should undergo CT or MRI studies to provide comprehensive cross-sectional information on ECFs and underlying disorders as a consistent basis for appropriate treatment choice and planning. Multidetector CT is preferred in uncooperative or severely ill patients such as those in early postoperative hospitalisation, because it obtains high-spatial resolution images in seconds, thus limiting motion or peristalsis artefacts. In the setting of ECF, intravenous CM is warranted unless contraindicated. Orally administered CM opacification may be helpful in patients with scarce intra-abdominal fat, to ease differentiation of bowel loops from extraluminal structures and abnormal collections; unfortunately, most patients who recently underwent surgery have ileus or obstruction and are unable to drink diluted CM. Alternatively, CT-fistulography (Fig. 2) with prior injection of iodinated CM such as 3% diluted iopamidol or iohexol through the EFO represents a useful one-stop-shop technique, which combines cross-sectional information with opacification of involved bowel tract. Image reconstruction and study interpretation along the sagittal plane are strongly recommended, as it provides the best visualisation of the ventral abdominal wall [4, 5].
The usual CT appearance of an ECF (Fig. 3) includes a tubular structure originating from a bowel loop, which directs ventrally or ventro-laterally through the peritoneum, crosses the abdominal wall muscles and fasciae to reach the cutaneous surface. ECFs may appear either collapsed or patent with gaseous and/or fluid content, in the latter case resulting in the characteristic “tram-track” appearance. Fistulous walls may be more or less thick, sometimes measuring up to one centimetre (Fig. 3C, D). The formation of a peripherally enhancing abscess with fluid and gaseous content along the ECF track (Fig. 4) should be reported, since it generally modifies the therapeutic approach.
In our experience, postsurgical ECFs often develop in cachectic patients with very thin subcutaneous and muscular planes of the ventral abdomen following repeated surgeries. The involved bowel loops tend to converge towards the ECF site and adhere closely to the peritoneal serosa (Figs. 2 and 5); not unusually, an ECF develops within a post-incisional hernia (Fig.3C, D).
At CT, the EFO generally corresponds to a focal cutaneous retraction or depression, and is often surrounded by thickened inflamed skin (Figs. 3 and 4); alternatively, a frank cutaneous breach or discontinuity may be observed, particularly in high-output ECFs (Fig. 5).
The two key CT differential diagnoses of an ECF are represented by:
A recent laparotomic incision (Fig. 3A), which is differentiated by reviewing the surgical description and inspecting the patient’s abdomen, and
Those fistulas (with usual “tram-track” CT appearance), which drain externally an intra-abdominal postsurgical collection (Fig. 6A, B), but lack communication with the bowel.
MRI technique and findings
Borrowing from extensive experience with perianal fistulas, MRI has intrinsically superior soft tissue contrast compared to CT and may, therefore, better define the fistulous tract; furthermore, MRI is appealing to both radiologists and patients because of absent ionising radiation exposure. However, in critically ill patients such as those in the early postoperative days, MRI is hampered by respiratory and peristaltic artefacts from bowel obstruction or ascites. In patients who can sufficiently cooperate, MRI protocols to investigate ECFs should rely on multiplanar fluid-sensitive T2-weighted images including the anterior abdominal wall; the use of fat suppression techniques in at least one plane is recommended to improve detection of oedema and inflammation in the intra-abdominal and subcutaneous fat. Additionally, intravenous administration of gadolinium CM is helpful to visualise hypervascularity of ECF walls, abscess collections and surrounding fat planes, which is best appreciated on volumetric fat-suppressed T1-weighted gradient-echo sequences such as T1 high-resolution isotropic volume excitation (THRIVE), liver acquisition with volume acquisition (LAVA) or volumetric interpolated breath-hold examination (VIBE).
On heavily T2-weighted MRI sequences, the ECF is seen as a fluid-filled hyperintense tubular structure coursing through the abdominal wall and subcutaneous fat to reach the EFO. The fistulous walls show variable, generally intermediate signal intensity on both T1- and T2-weighted acquisitions, with corresponding “tram-track” enhancement (Fig. 7) on post-gadolinium images. Over time, persistent ECFs tend to develop thicker walls with lower T2-weighted signal from fibrosis, and decreasing intensity of contrast enhancement. Unfortunately, in our experience identification of the presence or absence of bowel communication is generally more challenging at MRI (Fig. 6C, D) compared to CT [4, 5].
Treatment
Currently, the majority of postoperative ECFs tend to heal with conservative measures, endoscopic or percutaneous therapies. The latter consist in local injection of sealants such as cyanoacrylic glue (Glubran 2, GEM, Viareggio, Italy), and is rapidly becoming the preferred option as it achieves therapeutic success in a single session in almost two-thirds of cases, without any complications [5, 13].
Endoscopic positioning of clips and stents is the mainstay option when a leaking bowel anastomosis is present. Surgical repair is nowadays reserved for selected cases and remains associated with significant morbidity; high expertise is required to perform adhesiolysis and bowel resection at the internal fistula opening; unfortunately, postoperative ECF recurrence is not uncommon (16–21% of cases) [3, 14].
Enterocutaneous fistulas in chronic inflammatory bowel diseases
Clinical features
In patients with IBD, enterocutaneous fistulas may be either spontaneous or postoperative. The former situation results from the characteristic transmural inflammation of the affected enteric wall, which leads to penetration into the adjacent tissues, sometimes involves the abdominal wall and may ultimately reach the superficial tissues. In the vast majority of cases, ECFs arise from the diseased distal ileum and are associated with long-standing or active fistulising CD; exceptionally, an ECF may be the initial manifestation of an undiagnosed IBD. Albeit uncommon, CD still represents the main cause of non-iatrogenic ECFs and should therefore be suspected in a non-healing spontaneous fistula in a young or middle-aged, otherwise healthy patient [15, 16].
Cross-sectional imaging
According to the European Crohn’s and Colitis Organisation (ECCO) statements, CT- and MR-enterography with oral luminal distension represent the ideal techniques for imaging diagnosis and follow-up of CD, with similar indications and diagnostic accuracy; the latter modality is increasingly used since it does not use ionising radiation. In selected patients, water-enema multidetector CT may be useful to visualise the extent, mural and extraluminal changes of colonic IBD. In urgent conditions, standard contrast-enhanced CT is widely used and highly helpful when acute CD complications such as perforation, obstruction, fistula, or abscess formation are suspected [17, 18].
Particularly in patients with penetrating CD, the anterior abdominal wall should be carefully scrutinised on cross-sectional imaging studies. Sometimes unexpected or subtle, ECFs are recognised at CT as “tram-track” structures with fluid and/or gaseous content (Fig. 8), which generally depart from the site of active disease, entero-enteric fistulas, or anastomotic CD recurrence. With MRI, fluid-filled ECFs are well recognised along their course from the bowel to the skin (Fig. 9). In the setting of active IBD, a characteristic appearance is the mucosal contrast enhancement, which is generally prominent and appreciated on either CT (Fig. 8) and on fat-suppressed MRI sequences (Figs. 9 and 10). More common than with post-surgical ECFs, abscess formation is characteristic of CD: with both modalities, abscess collections with peripheral enhancement, and mixed air, fluid and dense content are easily detected at either internal opening or along the subcutaneous track (Fig. 10) [19, 20].
Post-surgical enterocutaneous fistulas in CD
Alternatively, an ECF may occur within a few weeks or months after IBD surgery, often through a previous abdominal scar and without residual or recurrent disease; clinically, this situation is commonly associated with limited physical findings due to use of steroids or immunomodulators.
In patients who received surgery recently, multidetector CT (Fig. 11A–C) is preferred to confirm and visualise ECFs, with similar imaging findings to their spontaneous counterparts. Unfortunately, interpretation of cross-sectional imaging studies shortly after IBD surgery is generally difficult due to a combination of limited intra-abdominal fat and of postoperative changes such as diffuse oedema at resection site and in the mesentery, peritoneal fluid, and CM enhancement; in our experience this is particularly true with MRI (Fig. 11D–F) [15, 16].
Treatment
The optimal treatment of enterocutaneous fistulas in CD remains debated: in the past, surgical resection of the diseased bowel plus fistula debridement through abdominal wall and subcutaneous planes was generally performed. In the last decade, medical therapy changed with introduction of biologics and immunomodulators. Following experience with perianal inflammatory disease, monoclonal antibodies against tumour necrosis factor are increasingly used: with correct patient selection, in the absence of stenosis and complex fistulas, infliximab achieves good response in postoperative and, to a minor extent, spontaneous ECFs too [16, 21, 22].
Special situation: malignant fistulas in Crohn’s disease
In patients with long-standing CD, small bowel adenocarcinoma (SBAC) occurs 33 times more commonly than in the general population. Unfortunately, its unspecific manifestations mimic those of active or obstructive CD, resulting in frequently delayed diagnosis at an advanced stage with disseminated disease [23, 24].
Sometimes, SBAC may penetrate through the anterior abdominal wall and fistulise to the skin (Fig. 12), a situation that is easily misinterpreted as the usual, spontaneous CD-related ECF unless thorough imaging is obtained. Unfortunately, differentiation of SBAC from either acute inflammatory or fibrotic CD is challenging. The commonest cross-sectional imaging patterns include ileal mass, long stricture with heterogeneous submucosa, short severe stenosis with upstream bowel dilatation, irregular asymmetric circumferential thickening. Suspicious features include mural thickness > 1 cm, abrupt “shouldering” transition, lost mural stratification, soft-tissue attenuation or solid MRI signal intensity, irregular serosal nodularity, and adenopathies (Fig. 12) [25–27].
The rare possibility of SBAC should be considered in patients with worsening CD symptoms after long quiescence and in non-healing ECFs despite treatment. Albeit difficult, preoperative diagnosis of malignant ECF in CD impacts treatment since it requires en bloc resection plus chemotherapy [23, 24]. Alternatively, the development of squamous cell carcinoma in chronic CD-related ECF has been occasionally reported [28].
Irradiation
Albeit most patients receiving abdominal or pelvic irradiation develop some degree of radiation enteritis, post-radiation ECF are increasingly rare and develop at least 4–6 months after radiotherapy. Unfortunately, irradiation further increases complexity of management, due to a combination of three factors: a) low likelihood of spontaneous closure; b) poor healing and high risk of dehiscence following surgery on irradiated bowel; c) delayed or impossible adjuvant or palliative therapies in presence of an ECF [4].
Tumour-related enterocutaneous fistulas
The possibility of an underlying malignancy should be considered when faced with a spontaneous ECF in an adult or elderly patient without history of recent surgery or IBD. This situation is increasingly rare since most colorectal malignancies are currently diagnosed and treated at an early or preclinical stage, but are strongly associated (over 50% of cases) with disseminated disease, impaired quality of life and high 30-day mortality [29, 30].
Tumour-related ECFs result from either superinfection (Fig. 13) or fistulisation through the abdominal wall muscles (Fig. 14). In both cases, CT and MRI are crucial in identifying solid, more or less homogeneous and enhancing neoplastic masses (Fig. 13) and the possible presence of abscess collections requiring drainage. Alternatively, cross-sectional imaging suggests ECF-associated colorectal tumour when faced with irregular or asymmetric mural thickening (Fig. 14); features such as short segmental involvement, abrupt transition, lost mural stratification and lymphadenopathy further support a diagnosis of malignancy [31–33].
The ideal curative surgery is en-bloc removal of fistulising tumour along with the involved abdominal wall along the ECF track, plus derivative colostomy or ileostomy. Alternative options include palliative resection, bypass or stoma in unresectable tumours [10, 30].
Conclusion
Nowadays, most patients with ECFs undergo multidetector CT or MRI studies to provide comprehensive cross-sectional assessment as a consistent basis for appropriate treatment choice and planning. In fact, visualisation of the underlying conditions (such as postoperative anastomotic leak, bowel obstruction, abscesses amenable to drainage, active or stricturing CD, fistulising or recurrent tumour) allows directed treatment, thus resulting in decreased rates of failed conservative management and higher likelihood of therapeutic success [4, 5].
References
- 1.Murphy J, Hotouras A, Koers L, et al. Establishing a regional enterocutaneous fistula service: the Royal London hospital experience. Int J Surg. 2013;11:952–956. doi: 10.1016/j.ijsu.2013.06.011. [DOI] [PubMed] [Google Scholar]
- 2.Orangio GR. Enterocutaneous fistula: medical and surgical management including patients with Crohn's disease. Clin Colon Rectal Surg. 2010;23:169–175. doi: 10.1055/s-0030-1262984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Visschers RG, van Gemert WG, Winkens B, et al. Guided treatment improves outcome of patients with enterocutaneous fistulas. World J Surg. 2012;36:2341–2348. doi: 10.1007/s00268-012-1663-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Felipe de Campos-Lobato L, Vogel JD. Enterocutaneous fistula associated with malignancy and prior radiation therapy. Clin Colon Rectal Surg. 2010;23:176–181. doi: 10.1055/s-0030-1262985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Lee JK, Stein SL. Radiographic and endoscopic diagnosis and treatment of enterocutaneous fistulas. Clin Colon Rectal Surg. 2010;23:149–160. doi: 10.1055/s-0030-1262982. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Gyorki DE, Brooks CE, Gett R, et al. Enterocutaneous fistula: a single-centre experience. ANZ J Surg. 2010;80:178–181. doi: 10.1111/j.1445-2197.2009.05086.x. [DOI] [PubMed] [Google Scholar]
- 7.Williams LJ, Zolfaghari S, Boushey RP. Complications of enterocutaneous fistulas and their management. Clin Colon Rectal Surg. 2010;23:209–220. doi: 10.1055/s-0030-1263062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Gu GL, Wang L, Wei XM, et al. Necrotizing fasciitis secondary to enterocutaneous fistula: three case reports. World J Gastroenterol. 2014;20:7988–7992. doi: 10.3748/wjg.v20.i24.7988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Redden MH, Ramsay P, Humphries T, et al. The etiology of enterocutaneous fistula predicts outcome. Ochsner J. 2013;13:507–511. [PMC free article] [PubMed] [Google Scholar]
- 10.Chamberlain RS, Kaufman HL, Danforth DN. Enterocutaneous fistula in cancer patients: etiology, management, outcome, and impact on further treatment. Am Surg. 1998;64:1204–1211. [PubMed] [Google Scholar]
- 11.Foda M, Carlson MA. Enterocutaneous fistula associated with ePTFE mesh: case report and review of the literature. Hernia. 2009;13:323–326. doi: 10.1007/s10029-008-0441-6. [DOI] [PubMed] [Google Scholar]
- 12.Tonolini M, Ippolito S. Multidetector CT of expected findings and early postoperative complications after current techniques for ventral hernia repair. Insights Imaging. 2016;7:541–551. doi: 10.1007/s13244-016-0501-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Mauri G, Pescatori LC, Mattiuz C, et al. Non-healing post-surgical fistulae: treatment with image-guided percutaneous injection of cyanoacrylic glue. Radiol Med. 2017;122:88–94. doi: 10.1007/s11547-016-0693-7. [DOI] [PubMed] [Google Scholar]
- 14.Lee SH. Surgical management of enterocutaneous fistula. Korean J Radiol. 2012;13(Suppl 1):S17–S20. doi: 10.3348/kjr.2012.13.S1.S17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Cellini C, Safar B, Fleshman J. Surgical management of pyogenic complications of Crohn's disease. Inflamm Bowel Dis. 2010;16:512–517. doi: 10.1002/ibd.20984. [DOI] [PubMed] [Google Scholar]
- 16.Gomez-Senent S, Barreiro-de-Acosta M, Garcia-Sanchez V. Enterocutaneous fistulas and Crohn s disease: clinical characteristics and response to treatment. Rev Esp Enferm Dig. 2013;105:3–6. doi: 10.4321/S1130-01082013000100002. [DOI] [PubMed] [Google Scholar]
- 17.Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7:556–585. doi: 10.1016/j.crohns.2013.02.020. [DOI] [PubMed] [Google Scholar]
- 18.Norsa AH, Tonolini M, Ippolito S, et al. Water enema multidetector CT technique and imaging of diverticulitis and chronic inflammatory bowel diseases. Insights Imaging. 2013;4:309–320. doi: 10.1007/s13244-013-0239-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Griffin N, Grant LA, Anderson S, et al. Small bowel MR enterography: problem solving in Crohn's disease. Insights Imaging. 2012;3:251–263. doi: 10.1007/s13244-012-0154-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Baker ME, Hara AK, Platt JF, et al. CT enterography for Crohn's disease: optimal technique and imaging issues. Abdom Imaging. 2015;40:938–952. doi: 10.1007/s00261-015-0357-4. [DOI] [PubMed] [Google Scholar]
- 21.Fries W, La Malfa G, Costantino G, et al. Combined approach with biologics and surgery for enterocutaneous fistulas in Crohn's disease. Inflamm Bowel Dis. 2011;17:671–673. doi: 10.1002/ibd.21289. [DOI] [PubMed] [Google Scholar]
- 22.Amiot A, Setakhr V, Seksik P, et al. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID. Am J Gastroenterol. 2014;109:1443–1449. doi: 10.1038/ajg.2014.183. [DOI] [PubMed] [Google Scholar]
- 23.Elriz K, Carrat F, Carbonnel F, et al. Incidence, presentation, and prognosis of small bowel adenocarcinoma in patients with small bowel Crohn's disease: a prospective observational study. Inflamm Bowel Dis. 2013;19:1823–1826. doi: 10.1097/MIB.0b013e31828c84f2. [DOI] [PubMed] [Google Scholar]
- 24.Widmar M, Greenstein AJ, Sachar DB, et al. Small bowel adenocarcinoma in Crohn's disease. J Gastrointest Surg. 2011;15:797–802. doi: 10.1007/s11605-011-1441-x. [DOI] [PubMed] [Google Scholar]
- 25.Place V, Hristova L, Dray X, et al. Ileal adenocarcinoma in Crohn's disease: magnetic resonance enterography features. Clin Imaging. 2012;36:24–28. doi: 10.1016/j.clinimag.2011.03.006. [DOI] [PubMed] [Google Scholar]
- 26.Soyer P, Hristova L, Boudghene F, et al. Small bowel adenocarcinoma in Crohn disease: CT-enterography features with pathological correlation. Abdom Imaging. 2012;37:338–349. doi: 10.1007/s00261-011-9772-3. [DOI] [PubMed] [Google Scholar]
- 27.Weber NK, Fletcher JG, Fidler JL, et al. Clinical characteristics and imaging features of small bowel adenocarcinomas in Crohn's disease. Abdom Imaging. 2015;40:1060–1067. doi: 10.1007/s00261-014-0144-7. [DOI] [PubMed] [Google Scholar]
- 28.Pinto Pais T, Fernandes S, Carvalho J. Squamous cell carcinoma in enterocutaneous fistula associated with Crohn's disease: first case report. J Crohns Colitis. 2014;8:1142–1143. doi: 10.1016/j.crohns.2014.02.017. [DOI] [PubMed] [Google Scholar]
- 29.Gunay Y, Bircan H, Demiralay E, et al. Spontaneous enterocutaneous fistula: unusual presentation of colon cancer. Turk J Gastroenterol. 2013;24:458–459. doi: 10.4318/tjg.2013.0519. [DOI] [PubMed] [Google Scholar]
- 30.Osian G (2012) Emergency Surgery for Colorectal Cancer Complications: Obstruction, Perforation, Bleeding. Contemporary Issues in Colorectal Surgical Practice, Dr Yik-Hong Ho (Ed) InTech, Available from: http://www.intechopen.com/books/contemporary-issues-in-colorectal-surgicalpractice/emergency-surgery-for-colorectal-cancer-complications
- 31.Catalano O. Perforated carcinoma of the colorectum. Computerized tomography findings. Radiol Med. 1997;93:83–86. [PubMed] [Google Scholar]
- 32.Kim SW, Shin HC, Kim IY, et al. CT findings of colonic complications associated with colon cancer. Korean J Radiol. 2010;11:211–221. doi: 10.3348/kjr.2010.11.2.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Tonolini M, Bianco R. MRI and CT of anal carcinoma: a pictorial review. Insights Imaging. 2013;4:53–62. doi: 10.1007/s13244-012-0199-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Tonolini M, Sampietro G (2016) Malignant enterocutaneous fistula in Crohn's disease {Online}. EuroRAD http://www.eurorad.org/case.php?id=13194
- 35.Tonolini M (2016) Spontaneous cutaneous fistulisation of colon carcinoma {Online}. EuroRAD http://www.eurorad.org/case.php?id=13353